 This is a phase II study evaluating the safety and efficacy of Combretastatin A4 Phosphate CA4P combined with carboplatin and paclitaxel. Treatment is for a maximum of 6 consecutive 21-day cycles. Patients are randomized onto one of two CA4P dosing arms 45 or 63 mgm2. CA4P is administered on days 1, 8 and 15 of each cycle. Carboplatin and paclitaxel AUC 6 and 200 mgm2, respectively are administered on day 2 of each cycle. At least 2 DCE-MRI scans will be performed to evaluate the change in tumor blood flow following treatment with CA4P. 